AU2019284605A1 - Fused thiophene compounds - Google Patents

Fused thiophene compounds Download PDF

Info

Publication number
AU2019284605A1
AU2019284605A1 AU2019284605A AU2019284605A AU2019284605A1 AU 2019284605 A1 AU2019284605 A1 AU 2019284605A1 AU 2019284605 A AU2019284605 A AU 2019284605A AU 2019284605 A AU2019284605 A AU 2019284605A AU 2019284605 A1 AU2019284605 A1 AU 2019284605A1
Authority
AU
Australia
Prior art keywords
alkyl
optionally substituted
compound
mmol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019284605A
Other languages
English (en)
Inventor
Kyle W. H. Chan
Aparajita Hoskote Chourasia
Paul E. Erdman
Leah Fung
Frank Mercurio
Robert Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioTheryX Inc
Original Assignee
BioTheryX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioTheryX Inc filed Critical BioTheryX Inc
Publication of AU2019284605A1 publication Critical patent/AU2019284605A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2019284605A 2018-06-13 2019-06-11 Fused thiophene compounds Abandoned AU2019284605A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684495P 2018-06-13 2018-06-13
US62/684,495 2018-06-13
PCT/US2019/036581 WO2019241271A1 (en) 2018-06-13 2019-06-11 Fused thiophene compounds

Publications (1)

Publication Number Publication Date
AU2019284605A1 true AU2019284605A1 (en) 2020-12-10

Family

ID=67263033

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019284605A Abandoned AU2019284605A1 (en) 2018-06-13 2019-06-11 Fused thiophene compounds

Country Status (8)

Country Link
US (2) US11191769B2 (https=)
EP (1) EP3807283A1 (https=)
JP (1) JP7365059B2 (https=)
CN (1) CN112601751B (https=)
AU (1) AU2019284605A1 (https=)
CA (1) CA3101335C (https=)
TW (1) TWI826463B (https=)
WO (1) WO2019241271A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN116583509A (zh) * 2020-10-07 2023-08-11 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
CN120303264A (zh) 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
CN119371398A (zh) * 2023-07-25 2025-01-28 安道麦阿甘有限公司 用于制备噻吩酮的新路线
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
AU2016266942B2 (en) * 2015-05-22 2018-10-18 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CA3043938A1 (en) * 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Also Published As

Publication number Publication date
CN112601751B (zh) 2024-04-02
US20220088025A1 (en) 2022-03-24
EP3807283A1 (en) 2021-04-21
JP2021527098A (ja) 2021-10-11
WO2019241271A1 (en) 2019-12-19
CA3101335C (en) 2024-01-09
TW202000674A (zh) 2020-01-01
CN112601751A (zh) 2021-04-02
US11191769B2 (en) 2021-12-07
US20200000814A1 (en) 2020-01-02
JP7365059B2 (ja) 2023-10-19
TWI826463B (zh) 2023-12-21
CA3101335A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
US11191769B2 (en) Fused thiophene compounds
US11400084B2 (en) Aminoamide compounds
US10889593B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US11236103B2 (en) Bifunctional compounds
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
US11352338B2 (en) Substituted isoindolinones
US10584133B2 (en) Thienopyrimidinone compounds
WO2019173224A1 (en) Deuterated compounds and chimeras and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application